Received Jun 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (RABAVERT) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | unknown | — |
| UNK | VACCINE NOT SPECIFIED (NO BRAND NAME) | UNKNOWN MANUFACTURER | 1 | Unknown | — |
The patient received Antirabies vaccine and dose of RabAvert vaccine; Case reference number US-BN-2025-000018 is a spontaneous case initially received from pharmacist via Med Communication (reference number: USBAV25-0038) on 06-Jan-2025 and concerns a male patient with unspecified age. The patient's medical history and concomitant medication details were not provided. On unknown date, the patient had unspecified rabies exposure. On 29-Dec-2024, unknown of time after exposure to rabies, the patient received first dose of Rabies Vaccine Inactivated (rabies vaccine inact (human diploid) reported as Antirabies vaccine (batch number: unknown), at unknown dose, route or site of administration for indication post-exposure prophylaxis. On 06-Jan-2024, unknown of time after exposure to rabies, the patient received second dose of RabAvert vaccine along with its constituent parts prefilled syringe, needle for injection and needle for reconstitution (batch number: unknown), at unknown dose, route or site of administration for post-exposure prophylaxis (explicitly coded as 'Interchange of vaccine products'). At the time of initial report, it was unknown if the patient experienced any adverse events due RabAvert. No further information was provided.; Reporter's Comments: A male patient with unspecified age received the first dose of Rabies vaccine inactivated for indication post-exposure prophylaxis. An unknown of time after exposure to rabies, the patient received the second dose of RabAvert vaccine for post-exposure prophylaxis, which is considered as interchange of vaccine products. It was unknown if the patient experienced any adverse events due RabAvert. Interchange of vaccine products is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Interchange of vaccine products is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A male patient with unspecified age received the first dose of Rabies vaccine inactivated for indication post-exposure prophylaxis. An unknown of time after exposure to rabies, the patient received the second dose of RabAvert vaccine for post-exposure prophylaxis, which is considered as interchange of vaccine products. It was unknown if the patient experienced any adverse events due RabAvert. Interchange of vaccine products is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Interchange of vaccine products is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: NONE